{
    "output": [
        [
            "BioNTech",
            "ORG",
            "Raise",
            "$270 million",
            "FIN_INSTRUMENT"
        ],
        [
            "BioNTech",
            "ORG",
            "Operate_In",
            "Germany",
            "GPE"
        ],
        [
            "BioNTech",
            "ORG",
            "Has",
            "close to $950 million",
            "FIN_INSTRUMENT"
        ],
        [
            "BioNTech",
            "ORG",
            "Participates_In",
            "cancer immunotherapies development",
            "CONCEPT"
        ],
        [
            "BioNTech",
            "ORG",
            "Control",
            "around 700 employees",
            "PERSON"
        ],
        [
            "BioNTech",
            "ORG",
            "Has",
            "corporate partnerships",
            "SECTOR"
        ],
        [
            "BioNTech",
            "ORG",
            "Has",
            "majority owners Thomas and Andreas Struengmann",
            "PERSON"
        ],
        [
            "BioNTech",
            "ORG",
            "Has",
            "latest Series A financing",
            "FIN_INSTRUMENT"
        ],
        [
            "Personalized cancer vaccine",
            "PRODUCT",
            "Impact",
            "cancer patients",
            "PERSON"
        ],
        [
            "Personalized cancer vaccine",
            "PRODUCT",
            "Relate_To",
            "immunotherapy drugs",
            "PRODUCT"
        ],
        [
            "Immunotherapy drugs",
            "PRODUCT",
            "Produce",
            "Merck & Co",
            "ORG"
        ],
        [
            "Immunotherapy drugs",
            "PRODUCT",
            "Produce",
            "Bristol-Myers Squibb",
            "ORG"
        ],
        [
            "Immunotherapy drugs",
            "PRODUCT",
            "Produce",
            "Roche",
            "ORG"
        ]
    ]
}